Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Lung Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAlpha Tau Medical LTD.
About this trial
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for treatment of recurrent Lung Cancer .
Eligibility criteria
Qualifiers
Histologically and/or cytologically proven recurrent mediastinal tumors
Target lesion is technically amenable for at least 50% coverage by the Alpha DaRT seeds as determined by the treating physician
Up to two treatable lesions
Interstitial radiation indication validated by a multidisciplinary team.
Disqualifiers
Concomitant chemotherapy or immunotherapy
Brain metastases Connective tissue disease (scleroderma, lupus)
Known hypersensitivity to any of the components of the treatment.
Patients undergoing systemic immunosuppressive therapy excepting intermittent, brief use of systemic corticosteroids.
Trial design
Treatments tested in this trial
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Treatment groups
10 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov